|
|
Article: Melanoma trial shows value of surgery at stage IV: Canvaxin disappoints in phase III study.(News)
- Article from:
- Skin & Allergy News
- Article date:
- May 1, 2006
- Author:
CopyrightCOPYRIGHT 2006 International Medical News Group. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
SAN DIEGO -- In a surprising twist, a failed phase III vaccine trial has shown promise for surgery in stage IV melanoma.
Investigators stopped recruiting patients to the international randomized, double-blind trial after an interim analysis conducted by an independent Data Safety and Monitoring Board indicated onamelatucel-L (Canvaxin) had little chance of outperforming placebo.
Canvaxin did as well as expected in the trial, but the placebo arm did better than predicted, according to data Dr. Donald L. Morton presented at a symposium sponsored by the Society for Surgical Oncology.
At 5 years, 40% of patients in both arms of the trial were still ...